Cidara Therapeutics
CDTX
CDTX was delisted on the 6th of January, 2026.
40 hedge funds and large institutions have $184M invested in Cidara Therapeutics in 2024 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 14 increasing their positions, 3 reducing their positions, and 4 closing their positions.
416% more capital invested
Capital invested by funds: $35.6M → $184M (+$148M)
367% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 3
325% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 4
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
50.5% more ownership
Funds ownership: 46.99% → 97.5% (+51%)
48% more funds holding
Funds holding: 27 → 40 (+13)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
TCG Crossover Management
Palo Alto,
California
|
+$16.3M |
| 2 |
VA
VR Adviser
New York
|
+$12.4M |
| 3 |
VC
Vivo Capital
Palo Alto,
California
|
+$10.9M |
| 4 |
BI
BVF Inc
San Francisco,
California
|
+$6.33M |
| 5 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$6.33M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$3.97M |
| 2 |
ACM
Alethea Capital Management
Mercer Island,
Washington
|
-$1.07M |
| 3 |
Renaissance Technologies
New York
|
-$35.7K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$12K |
| 5 |
Russell Investments Group
London,
United Kingdom
|
-$9.19K |
CDTX Hedge Fund Activity: Q4 2024 in Review
40 of the 7,605 institutional investors tracked by Wall St. Rank reported a position in Cidara Therapeutics (CDTX) for Q4 2024, worth a combined $184M — up 416% from $35.6M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new CDTX positions and 4 closed out — a net gain of 13 holders — while 14 added to existing stakes and 3 trimmed.
The largest buyer was TCG Crossover Management, opening a new position worth an estimated $16.3M. The largest seller was Monashee Investment Management, exiting entirely with an estimated $3.97M sold.
- 40 institutional investors held Cidara Therapeutics (CDTX) as of Q4 2024, up from 27 in Q3 2024.
- Funds reported $184M of Cidara Therapeutics stock for Q4 2024, up 416% quarter-over-quarter.
- 17 funds opened new Cidara Therapeutics positions in Q4 2024 and 4 closed out, a net change of +13 holders.
- The largest Cidara Therapeutics buyer in Q4 2024 was TCG Crossover Management, an estimated $16.3M added.
- The largest Cidara Therapeutics seller in Q4 2024 was Monashee Investment Management, an estimated $3.97M sold.
Based on aggregated 13F filings for Q4 2024.